Global Companion Diagnostic Tests in Oncology Market: Snapshot
The global companion diagnostic tests in oncology market is expected to register phenomenal pace owing to increasing adoption of new tests, and rising shift from blockbuster drugs to personalized medicines, and targeted therapies. Increasing incidence of cancer, rising cost burden of cancer treatment, and increasing mortalities due to cancer, are some of the major reasons for increasing demand for new and technologically advanced treatment options, therapies, and drugs for the treatment of cancer. Increasing focus on research and development by various pharmaceutical and biotechnology companies, along with medical device companies, and increasing funding and grants for cancer research by various government agencies have led to high adoption of companion diagnostic tests in oncology. According to the research report, the global companion diagnostic tests in oncology market is expected to be worth US$13.6 bn by the end of 2025 from US$3.5 bn in 2016. During the forecast period of 2017 and 2025, the global market is projected to rise at a CAGR of 16.8%.
This 232 page report gives readers a comprehensive overview of the companion diagnostic tests in oncology market. Browse through 42 data tables and 89 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/companion-diagnostic-tests-market.html
EGFR Biomarker to Remain Popular Amongst Pharmaceutical Companies
Among the biomarker segment, the EGFR biomarker segment accounted for the largest share of the global companion diagnostic tests in oncology market in 2016. It is expected to register highest CAGR during the forecast period of 2017-2025, owing to major factors such as increasing incidence of lung cancer, and rising R&D in biomarker segment. The HER2 and KRAS biomarkers are expected to register high CAGR during the forecast period, due to increasing incidence of cancer, and rising adoption of biomarker by pharmaceutical companies and research institutes. Analysts expect that the EGFR biomarker segment will register a CAGR of 18.4% over the forecast period.
Among the cancer types segment, the breast cancer segment accounted for the largest share of the global companion diagnostic tests in oncology market in 2016. However lung cancer segment is expected to register highest CAGR during the forecast period of 2017-2025, owing to increasing incidence of lung cancer in developing countries. This shift is attributable to the increased smoking and rising biomarker research for the lung cancer treatment. According to statistics from the World Health Organization (WHO), in 2013, an estimated 1.9 million new cases of lung cancer were diagnosed, and the stats reveled that less developed regions including the emerging countries such as China, India, and other countries, had the highest incidence of lung cancer, owing to rising smoking habits and poor air quality in these countries.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving companion diagnostic tests in oncology market during 2017 – 2025: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4684
North America to Remain Dominant with Higher Acceptance of Technologies
Geographically, the global companion diagnostic tests in oncology market is segmented into North America, the Middle East and Africa, Asia Pacific, Europe, and Latin America. Analysts expect that North America will continue to dominate the global market due to the higher acceptance of technology in the region. Furthermore, better rate of diagnoses in the region is also likely to favor the regional market’s growth. By the end of 2025, the regional market is projected to account for a share of 37.5% in the global market. On the other hand, Asia Pacific is also expected to offer lucrative opportunities due to high rate of unmet medical needs in the emerging economies of the region.
Major players having presence in the global companion diagnostic tests in oncology market include F. Hoffman LA Roche Ltd., QIAGEN, Illumina, Inc., Abbott, Agilent Technologies, Inc., Genomic Health, Inc., bioMerieux SA, BioGenex, AGENDIA NV, Siemens Healthcare GmBH, and Thermo Fisher Scientific, Inc., among others.
Global Cancer Biomarkers Market: Snapshot
Cancer is a complex and potentially fatal disease that is primarily caused through environmental factors resulting in gene mutations affecting critical cell-regulatory proteins. These factors may act together or in a sequence to trigger tumor formation. Rising incidences of cancer and increasing healthcare expenditure are expected to aid the global cancer biomarkers market. The global market for cancer biomarkers is expected to grow at an exponential rate benefiting from the recent advances in technology, favorable government initiatives and funding.
Moreover, the development in companion diagnostics and recent breakthrough in detection techniques such as proteomics, metabolomics, genomics and transcriptomics are further expected to boost the demand for cancer biomarkers. Cancer biomarker is critical in improving early detection and treatment of any cancer type. Awareness and screening for cancer have increased over the last couple of decades resulting in early diagnosis of cancer and subsequent reduction of mortality. However, the ultimate goal of reducing mortality in late-stage cancer has not been satisfactorily achieved.
This 157 page report gives readers a comprehensive overview of the cancer biomarkers market. Browse through 18 data tables and 64 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/cancer-biomarkers-market.html
Besides this, the cancer biomarkers market is expected to gain from the rising geriatric population, increasing incidences of cancer, and increasing prevalence of tumor. Technological advancements in the field of biomarkers resulting in new and innovative products have increased the safety, improved efficacy and reduced the side effects. Spurred by these factors, the global cancer biomarkers market is forecast to exhibit a CAGR of 11.8% between 2017 and 2025. At this pace, the market is expected to reach US$27.63 bn by the end of 2025 from US$10.25 bn in 2016.
Lung Cancer Emerges as Leading Segment Based on Disease Indication
The CTC tests segment by test type accounted the largest share of the global cancer biomarkers market in 2016, and is expected to dominate the market during the forecast period from 2017 to 2025. Factors such as increase in prevalence of the various types of tumor and increasing incidences of cancer related to the vital organs drives the CTC tests segment. Although associated with non-drivers of selection, such as quick and easy order processing and availability from a contracted manufacturer, the cancer biomarkers market presents immense competition for new market players.
The lung cancer segment in terms of disease indication has the largest market share of the global cancer biomarkers market in 2016, and is expected to grow during the forecast period due to increasing prevalence of lung cancer in developing countries, growing cigarette smoking among the population, rising geriatric population, and technological advancements with regard to lesser side effects associated with biomarkers test and early detection of the illness drive demand for lung cancer diagnosis globally.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving cancer biomarkers market during 2017 – 2025: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=479
North America to Remain Dominant Regional Market through Forecast Period
North America dominated the global cancer biomarkers market in 2016 and is expected to remain dominant through the forecast period. This is due to high prevalence of cancer, increasing health care expenditure leading to increase in demand for better diagnostic tests and health care services, and number of technological advancements in the field of cancer biomarkers. However, the market in Asia Pacific is projected to register a significant growth rate by 2025 due to availability of large patient pool and increasing awareness about health. In addition, high percentage of geriatric population, and increasing disposable income are expected to propel the market.
Major players operating in the global cancer biomarkers market include Abbott Laboratories, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, QIAGEN, Merck & Co., Inc., Hologic, Inc., Novartis AG, bioMérieux SA, Genomic Health, Inc., are among others.
Global Human Microbiome Market: Snapshot
With ample unmet needs, the global market for human microbiome exhibits high potential of growth. The market is set to emerge as a lucrative business in the near future, thanks to the increasing emphasis on diagnosis and treatment of various underrated diseases. The worldwide human microbiome market will be US$2.2 bn in 2020. The lack of targeted drugs for specific conditions, such as ulcerative colitis and C.difficile infection across the world makes this market highly opportune for players to set their innovative drug ideas on the path to commercial success. Driven by these factors, the opportunity in this market is slated to rise at a CAGR of 9.80% between 2020 and 2024 and reach US$3.2 bn by the end of 2024.
This 176 page report gives readers a comprehensive overview of the human microbiome market. Browse through 31 data tables and 87 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/human-microbiome-market.html
Microbiome diagnostics and microbiome therapeutics are the two prominent sections of the global human microbiome market. Currently, the market is in the budding phase, with most of the therapies still being in preclinical or clinical (phase I or phase II) stage. The diagnosis technology is also in the development phase and the leading companies have begun to allocate funds for the research and development and the management of clinical studies for their innovative class of therapies. All these factors are likely to propel this market significantly over the next few years. The human microbiome therapeutics market is likely to report a CAGR of 9.20% during the period of 2020 to 2024, whereas the market for human microbiome diagnostics is anticipated to rise at an 8.60% CAGR between 2018 and 2024.
North America to Report Continued Leadership
North America, Asia Pacific, the Middle East and Africa, Europe, and Latin America are the key regional markets for human microbiome across the world. Thanks to the presence of a state-of-art medical and healthcare industry and early adoption of technology, North America has occupied the top position in the global market. Researchers expect that the rising number of venture-capital funded start-ups and the increasing investments by leading players for research and development of drugs will support the North America market for human microbiome over the forthcoming years, ensuring its dominance. The human microbiome therapeutics market in North America is anticipated to report a rise at a CAGR of 9.10% between 2020 and 2024 while the region’s human microbiome diagnostics market will progress at an 8.80% CAGR from 2018 to 2024.
Europe, which acquired the second position in the global human microbiome market, is projected to maintain its position over the years to come. The U.K. and France have emerged as the key domestic markets for human microbiome in Europe. The high investments by companies in this domain are expected to boost both these domestic markets in the next few years. Apart from this, countries, such as Sweden and the Netherlands, are also anticipated to contribute well to the Europe market for human microbiome market in the near future.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving human microbiome market during 2018 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3999
Metagenomic Sequencing to Outpace 16s rRNA in Future
On the basis of technology, the global market for human microbiome is classified into 16s rRNA sequencing and metagenomic sequencing. Both the technology are equally popular platforms for detection in the microbiome-based diagnostics. However, the metagenomic sequencing segment is likely to surpass the 16s rRNA segment over the next few years, albeit by a small margin, as a large number of companies are opting for the diagnosis of a more comprehensive microbiome profile.
At the forefront of the global market for human microbiome are Vedanta Biosciences, Synthetic Biologics Inc., Seres Therapeutics, Second Genome, uBiome Inc., Rebiotix Inc., Osel Inc., MicroBiome Therapeutics LLC., Metabiomics Corp., Enterome Biosciences SA, and AO Biome LLC. Some of the other prominent participants in this market are Metabogen AB, Becton Dickinson & Co., Evelo Biosciences, ARTPred, MaaT Pharma, Blue Turtle Bio Technologies, Axial Therapeutics, Whole Biome, 4D Pharma, Symbiotix Therapies, Phi Therapeutics, Synlogic, and Biospherex LLC.
Via a fresh intelligence study, Transparency Market Research (TMR) reports that the global temperature monitoring devices market is heavily dependent on technological advancements, and that the competitive landscape will remain tilted towards those companies who aggressively develop products that meet the desired outcomes. The report observes that there is strong clinical needs for different temperature monitoring modalities in hospitals. The caregivers are forced to stock and depend on multiple temperature monitoring methods, with each method introducing variation due to accuracy and technique. The 3M Bair Hugger temperature monitoring system, formally known as 3M SpotOn system, can be one such example. The device provides a non-invasive method with accurate temperature measurement, which can be used preoperatively and in any type of anesthesia.
The report identifies 3M Company, Koninklijke Philips N.V., Drägerwerk AG & Co. KGaA, Cosinuss GmbH, Helen of Troy Limited, Terumo Corporation, Welch Allyn, Inc., Omron Healthcare, Microlife Corporation, C.R. Bard, and Briggs Healthcare as some of the prominent participants of the global temperature monitoring devices market. As per the projections of the TMR report, the demand in the global temperature monitoring devices market will augment at a CAGR of 4.1% during the forecast period of 2017 to 2025. Everything put together, the temperature monitoring devices market, across the world, will be worth US$3.23 bn by 2025, considerably up from its evaluated valuation of US$2.27 bn in 2016.
Obtain Report Details: http://www.transparencymarketresearch.com/temperature-monitoring-devices-market.html
Based on product-type, table top temperature monitoring devices, which is further sub-segmented into non-invasive vital signs monitoring devices and continuous core body temperature monitoring devices, served the maximum demand, whereas non-invasive was most in-demand technique. The global market continues to gain significant share of the overall demand for temperature monitoring devices from wellness application, while geographically, North America has been detected a highly lucrative region. The developed countries of the U.S. and Canada, who have robust healthcare infrastructure and high adoptability-rate of new technology, dominate the demand from North America temperature monitoring devices market.
Technologically-advanced Products Gaining Popularity
For proper care, vital signs monitoring including temperature monitoring is more like the first line of treatment, helping physicians to assess the health status of patients. Temperature monitoring devices comprise of diverse product types, which are used in various applications, including wellness and clinical. A major chunk of product offering is seen among hand held temperature monitoring devices segment that include digital thermometer and infra-red aural thermometers, whereas the segment like wearable continuous monitoring thermometers is characterized by increasing product launches by emerging market players.
The global market for temperature monitoring devices is gaining strong traction from the increasing number of new entrants in the wearable segment. Their products offer continuous monitoring thermometers and smart temperature patches. Demand for new and improved temperature monitoring devices continues to rise, regardless of the presence of existing branded devices. This is primarily due to significant increase in the use of wearable health trackers, rising adoption of high value table top temperature monitors among clinical applications, and rising awareness for continuous patient vital signs tracking to reduce the risk of emergency ICU admissions.
Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2159
Value Added Service Assistance Opening New Opportunities
As per the author of the report, the strengthening of market penetration through distribution and licensing agreements with leading distributors, along with value added service assistance that offer real-time monitoring, primarily to the geriatrics, are major opportunities for the global temperature monitoring devices market.
The information presented in this review is based on a Transparency Market Research report, titled, “Temperature Monitoring Devices Market (Product Type – Table Top Temperature Monitoring Devices (Non-invasive Vital Signs Monitoring Devices and Continuous Core Body Temperature Monitoring Devices), Hand Held Temperature Monitoring Devices (Digital Thermometers and Infra-red Aural Thermometers), Wearable Continuous Monitoring Thermometers, and Temperature Monitoring Sensors & Smart Temperature Patches; Technique – Invasive and Non-invasive; Application – Clinical and Wellness; Distribution Channel – Institutional Sales (Hospitals, Clinics, Skilled Nursing Facilities, Long Term Care Centers, and Ambulatory Care Centers), Retail Sales (Retail Pharmacies, Drug Stores, and Online Sales)) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017 – 2025.”
Urine is normally carried from the kidneys to the bladder through long, narrow, muscular tubes called ureters. The passage of urine may become difficult if the ureter becomes obstructed due to conditions such as tumors, infections, kidney stone, etc. For such conditions, the physicians place an artificial tube, known as ureteral stent, intended to restore the flow of the bladder. Aging is the most common factor that leads to several types of urology diseases. The global aging population is a direct indication of the possible rise in the patients suffering with urological diseases. With the increasing conditions that obstruct the flow of urine, the use of urological stents have become the most fundamental and valuable technique in the urological practice.
Obtain Report Details: http://www.transparencymarketresearch.com/urinary-tract-stenting-market.html
A ureteral stent is specially designed a soft tube 10-12 inches in length that is placed in the ureter for draining urine from the kidney to the urinary bladder. These stents are coiled at both the end to stay in place in the urinary system and therefore also known as JJ stent, pig-tail stent of double J stent. Normally a person can have ureteral stents for not more than 3 to 6 months. If left for longer duration, there is a possibility of stone formation which makes removal of stents difficult. If a patient is required to have stent for a longer duration, he must be admitted in the hospital for stent change. This is a serious limitation for the usage ureteral stent. Several companies operating in the market are trying to overcome the issue of biofilm formation and mineralogical encrustation. Furthermore, there are ongoing research activities in the global urinary tract stenting market to modify the design, discovering novel stent coating and the basic composition materials of the stent. Usage of metal stents in urology is being recommended by some physicians which have not yet become a widespread practice. Some of the advancements required for the industry include anti-body coated stents, nanotube coating, radioactive stents, and absorbable magnesium metal stent. The successful trials of the technologies have a potential to drastically change the existing market dynamics in the global urinary stenting market.
The global market for urinary tract stenting can be segmented on the basis of application of urology stents into kidney stones treatment. The major segments in which urological stents are used include procedures such as lithotripsy, ureteroscopy, ureteroenoscopy, and percutaneous nephrolithotomy. Based on the procedures of removing the obstruction in the ureter, the market can be segmented into ureteral stenting, prostate stenting and urethral stenting.
Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11072
Based on the geography, the global urinary tract stenting market is segmented into four major regions, namely, North America, Europe, Asia-Pacific and Rest of the World. More than 2 million people in the U.S. are annually diagnosed for the presence of kidney stone. The number of people suffering from similar diseases is even higher in the Asia-Pacific and Rest of the World. The rising number of kidney stone patients in the world is expected to increase the number of treatment procedures at a faster rate than before eventually increasing the demand for the urinary tract stents. As the economic conditions in the emerging nations such as China, India, and Brazil are expected to improve in the near future, most of the market growth will be fuelled by demand from these countries.
Some of the key companies operating in the global urinary tract stenting market include Boston Scientific Corporation, C. R. Bard, Inc., Cook Medical, Inc., and Medline Industries, Inc., Pnn Medical A/S, and Allium Medical Solutions Ltd.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.